Evidence map›Paper›PMID 33508030›Full record

ArticlePloS one2021

An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States.

Miguel Sánchez-Romero, Vanessa di Lego, Alexia Prskawetz, Bernardo L Queiroz

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. The impact of COVID-19 vaccines on the Case Fatality Rate: The importance of monitoring breakthrough infections.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  4. Review
  5. Article
  6. Underdetection in a stochastic SIR model for the analysis of the COVID-19 Italian epidemic.Stochastic environmental research and risk assessment : research journal · 2022
    Article
  7. SARS-CoV-2 infections in 165 countries over time.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
  8. Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021
    Article
  9. Reducing COVID-19 Cases and Deaths by Applying Blockchain in Vaccination Rollout Management.IEEE open journal of engineering in medicine and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miguel Sánchez-RomeroWittgenstein Centre for Demography and Global Human Capital (IIASA, OeAW, University of Vienna), Vienna Institute of Demography/Austrian Academy of Sciences, Vienna, Austria.
Vanessa di LegoWittgenstein Centre for Demography and Global Human Capital (IIASA, OeAW, University of Vienna), Vienna Institute of Demography/Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-1317-3037
Alexia PrskawetzWittgenstein Centre for Demography and Global Human Capital (IIASA, OeAW, University of Vienna), Vienna Institute of Demography/Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-2850-6682
Bernardo L QueirozUniversidade Federal de Minas Gerais, Cedeplar, Belo Horizonte, State of Minas Gerais, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of COVID-19 infections is key for accurately monitoring the pandemics. However, due to differential testing policies, asymptomatic individuals and limited large-scale testing availability, it is challenging to detect all cases. Seroprevalence studies aim to address this gap by retrospectively assessing the number of infections, but they can be expensive and time-intensive, limiting their use to specific population subgroups. In this paper, we propose a complementary approach that combines estimated (1) infection fatality rates (IFR) using a Bayesian melding SEIR model with (2) reported case-fatality rates (CFR) in order to indirectly estimate the fraction of people ever infected (from the total population) and detected (from the ever infected). We apply the technique to the U.S. due to their remarkable regional diversity and because they count with almost a quarter of all global confirmed cases and deaths. We obtain that the IFR varies from 1.25% (0.39-2.16%, 90% CI) in Florida, the most aged population, to 0.69% in Utah (0.21-1.30%, 90% CI), the youngest population. By September 8, 2020, we estimate that at least five states have already a fraction of people ever infected between 10% and 20% (New Jersey, New York, Massachussets, Connecticut, and District of Columbia). The state with the highest estimated fraction of people ever infected is New Jersey with 17.3% (10.0, 55.8, 90% CI). Moreover, our results indicate that with a probability of 90 percent the fraction of detected people among the ever infected since the beginning of the epidemic has been less than 50% in 15 out of the 20 states analyzed in this paper. Our approach can be a valuable tool that complements seroprevalence studies and indicates how efficient have testing policies been since the beginning of the outbreak.

Indexed as

Bayes TheoremCOVID-19COVID-19 TestingFemaleHumansMaleModels, StatisticalMortalityPandemicsProbabilityRetrospective StudiesSARS-CoV-2Seroepidemiologic StudiesUnited States

Identifiers

PMID33508030
PMCPMC7842943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.